Lifestyle
- Regular exercise
- Stress management
- Adequate sleep
Total Iron Binding Capacity · Totale Eisenbindungskapazität
TIBC quantifies the total capacity of blood to bind iron with transferrin.
Reference ranges may vary slightly by laboratory and population. No significant sex-specific differences.
Total Iron Binding Capacity (TIBC) is a blood test that measures the maximum amount of iron that can be bound by proteins in the blood, primarily transferrin. It reflects the body's capacity to transport iron. Clinically, TIBC is important for diagnosing and differentiating types of anemia, especially iron deficiency anemia (IDA). Elevated TIBC is often observed in IDA, while low TIBC can be seen in conditions such as chronic disease anemia and hemochromatosis. In the context of athletic performance and longevity, researchers have found that lower TIBC levels may be associated with increased longevity, as seen in centenarians. This suggests that iron metabolism may play a role in aging processes. However, TIBC values can be influenced by various factors, including nutritional status, inflammation, and liver function. Testing should consider these confounders, and fasting is not typically required, although consistency in testing conditions is advised for accurate monitoring.
Klinische Bedeutung
Elevated TIBC typically indicates iron deficiency anemia, reflecting increased transferrin levels due to low iron stores. Reduced TIBC may indicate conditions such as anemia of chronic disease or hemochromatosis, where iron overload or inflammation affects transferrin production.
Progressively rising TIBC values may suggest worsening iron deficiency. Re-test in 4-6 weeks if clinically indicated.
Falling TIBC values could indicate resolution of iron deficiency or onset of conditions like chronic disease anemia.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a physician before starting iron supplementation, especially if not iron deficient.
Iron levels can vary throughout the day; morning tests are preferred.
Testing Frequency
Annually for individuals at risk of anemia or iron overload.
May affect
Current research suggests that reference ranges for total iron-binding capacity (TIBC) may vary significantly across populations, and optimal targets for TIBC in diagnosing iron deficiency anemia remain debated. Researchers have not yet established the influence of confounding factors such as inflammation and nutritional status on TIBC levels. Additionally, clinical questions regarding the predictive value of TIBC in assessing long-term outcomes in various patient populations, including those with chronic diseases, remain unanswered.
1,310
Total Citations
12
Human/RCT
13.5
Avg. Influence
2025
Latest
This study developed a comprehensive Malnutrition-Inflammation Score (MIS) for maintenance hemodialysis patients. Researchers found that the MIS, which includes total iron-binding capacity, correlated significantly with hospitalization and mortality rates, suggesting its potential as a predictor of clinical outcomes.
This article focused on the laboratory diagnosis of thalassemia. Researchers found that iron status, including total iron-binding capacity, is crucial for distinguishing thalassemia carriers from those with iron deficiency anemia.
Van Vranken Michele · American family physician · 2010
This study evaluated microcytosis, often found incidentally in patients. Researchers found that low ferritin levels suggest iron deficiency, and emphasized the importance of assessing total iron-binding capacity and other iron parameters to determine the cause of microcytosis.
Key findings
This genome-wide meta-analysis examined iron status biomarkers and their effects on all-cause mortality. Researchers found evidence of harmful effects associated with increased serum iron and transferrin saturation, contributing to understanding the genetic factors influencing iron status.
Murata Shunsuke, et al. · GeroScience · 2024
This study compared blood biomarker profiles of centenarians and non-centenarians over a 35-year period. Researchers found that higher levels of iron and total cholesterol, along with lower levels of total iron-binding capacity, were associated with reaching age 100. The study highlighted that centenarians exhibited more favorable biomarker values as they aged.
Key findings
This review examined iron deficiency anemia (IDA), a common condition affecting various populations. Researchers found that IDA is characterized by low serum iron, decreased transferrin saturation, and increased total iron binding capacity. They emphasized the importance of identifying underlying causes for effective management.
This article focused on microcytic anemia, primarily caused by iron deficiency. Researchers found that low serum ferritin is the best indicator for diagnosing iron deficiency anemia, and emphasized the need to investigate underlying causes when anemia is detected.
Researchers investigated the causal relationship between iron status and functional outcomes after ischemic stroke. They found that higher levels of total iron binding capacity and serum iron were associated with poorer functional outcomes, suggesting a potential modifiable risk factor.
This study assessed iron metabolism in nasopharyngeal carcinoma patients, finding lower levels of serum iron, TIBC, and transferrin compared to healthy controls. Researchers observed that the degree of iron deficiency correlated with tumor burden and metastasis.
Researchers compared different methods for estimating total iron binding capacity (TIBC) and their correlation with serum transferrin levels. They found that the direct method of TIBC estimation showed a strong positive correlation with serum transferrin, making it the most reliable method.
Research publications about TIBC over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer